Latest Breaking News On - Renal cancer oncology - Page 1 : comparemela.com
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
fool.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com.au Daily Mail and Mail on Sunday newspapers.
How these top ASX biotech shares performed in FY21
What company was the ASX’s best performing biotech share over FY21?
Sebastian Bowen has been a Motley Fool contributor since late 2018.
Sebastian found his passion for writing and educating others about shares and all things finance after completing his studies in political, economic and social science and enjoys bringing this passion to life at the Fool. His investment philosophy is a simple one - buying high-quality companies at prices that make sense. When he’s not researching his next investment at all hours of the morning, Sebastian enjoys classic movies and likes to unwind with a good book, newspaper or record.
Over the past 12 months, the
Telix Pharmaceuticals Ltd(ASX: TLX) share price has posted massive gains exceeding 150%. The Telix share price kicked off 2020 at $1.53, closed the year at $3.78 and is currently sitting at $3.86 per share.
So what has Telix done to achieve this remarkable pump for its share price?
Significant US Food and Drug Administration (FDA) wins
In January 2020, Telix announced that the US Food and Drug Administration (FDA) approved the recruitment of American participants in the company’s Zirconium Imaging in Renal Cancer Oncology (ZIRCON) study. This was an important milestone because it extended the Phase III study into new territory beyond Australia and Europe.